TriSalus Life Sciences, Inc. (TLSI)
4.97
-0.17
(-3.31%)
USD |
NASDAQ |
Sep 03, 15:33
TriSalus Life Sciences Total Liabilities (Quarterly) : 55.90M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 55.90M |
| March 31, 2026 | 58.17M |
| December 31, 2025 | 69.19M |
| September 30, 2025 | 63.19M |
| June 30, 2025 | 60.74M |
| March 31, 2025 | 63.00M |
| December 31, 2024 | 49.86M |
| September 30, 2024 | 47.91M |
| June 30, 2024 | 56.58M |
| March 31, 2024 | 52.81M |
| December 31, 2023 | 51.66M |
| September 30, 2023 | 25.07M |
| Date | Value |
|---|---|
| June 30, 2023 | 15.31M |
| March 31, 2023 | 14.21M |
| December 31, 2022 | 34.32M |
| September 30, 2022 | 12.16M |
| June 30, 2022 | 12.05M |
| March 31, 2022 | 14.28M |
| December 31, 2021 | 17.25M |
| September 30, 2021 | 20.37M |
| June 30, 2021 | 22.69M |
| March 31, 2021 | 23.65M |
| December 31, 2020 | |
| September 30, 2020 | 0.0435M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
| Savara, Inc. | 48.48M |
| Vericel Corp. | 132.82M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 62.45M |
| Shareholders Equity (Quarterly) | 6.55M |
| Debt to Equity Ratio | 5.256 |
| Current Ratio | 5.348 |
| Net Debt Paydown Yield | -0.09% |